Anti-Rheumatic Drugs - Estonia

Estonia

The Anti-Rheumatic Drugs market in Estonia is expected to witness substantial growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$6.73m by 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 0.90%, leading to a market volume of US$7.04m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with an estimated revenue of US$34,700.00m in 2024.
Estonia has seen a rise in demand for biologic anti-rheumatic drugs, reflecting a shift towards more targeted and effective treatments for rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Estonia is on the rise due to several factors.

Customer preferences: Estonians are becoming more health-conscious, leading to an increase in the demand for medications that treat chronic conditions such as rheumatoid arthritis. Additionally, the aging population is also contributing to the growth in demand for anti-rheumatic drugs.

Trends in the market: The anti-rheumatic drug market in Estonia is witnessing a shift towards biologics, which are more effective in treating rheumatoid arthritis. Patients are willing to pay a premium for these drugs as they offer better outcomes and improved quality of life. There is also an increasing trend towards self-injectable drugs, which allow patients to administer the medication themselves at home.

Local special circumstances: Estonia has a well-developed healthcare system, which provides universal health coverage to its citizens. The government has implemented several initiatives to improve access to healthcare, including the reimbursement of prescription drugs for chronic conditions such as rheumatoid arthritis. This has made it easier for patients to afford the high cost of biologics.

Underlying macroeconomic factors: Estonia has a stable economy, with a high level of economic freedom and a low unemployment rate. This has led to an increase in disposable income, which is being spent on healthcare. The government has also implemented policies to encourage foreign investment, which has led to the entry of multinational pharmaceutical companies in the Estonian market. This has increased competition and led to the availability of a wider range of anti-rheumatic drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.